Previous studies have demonstrated that NORAD promoted tumor proliferation and progression in non-small-cell lung cancer (Huang Q. et al., 2020), endometrial cancer (Han T. et al., 2020), and melanoma (Chen et al., 2019). The gene discussed is NORAD; the disease is endometrial cancer.